论文部分内容阅读
目的:探讨血必净注射液联合生长抑素治疗重症胰腺炎的临床疗效。方法:选取86例本病患者为研究对象,采用随机分组法分为对照组43例和治疗组43例。对照组予“基本治疗+生长抑素”治疗,治疗组予“基本治疗+生长抑素+血必净注射液”治疗。经治疗后,观察并记录两组患者的临床疗效和临床症状的改善(血、尿淀粉酶,C-反应蛋白量,胰腺水肿情况,住院时间)及患者住院期间并发症的发生率。结果:经治疗后,对照组总有效率为74.4%,治疗组总有效率为90.7%,组间差异有统计学意义(P<0.05);治疗组临床症状改善的情况明显优于对照组,组间差异有统计学意义(P<0.05);对照组并发症总发生率为16.7%,治疗组并发症总发生率为4.6%;组间差异有统计学意义(P<0.05)。结论:对于重症胰腺炎患者,在基本治疗的基础上,采用血必净注射液联合生长抑素内科保守治疗,其临床疗效显著,并发症少,能快速改善患者的临床症状。
Objective: To investigate the clinical efficacy of Xuebijing injection combined with somatostatin in the treatment of severe pancreatitis. Methods: A total of 86 patients with this disease were selected as study subjects and divided into control group (43 cases) and treatment group (43 cases) by randomization method. Control group to “basic treatment + somatostatin ” treatment, the treatment group to “basic treatment + somatostatin + Xuebijing injection ” treatment. After treatment, the clinical efficacy and clinical symptoms (blood, urine amylase, C-reactive protein, pancreatic edema, hospital stay) and the incidence of complications during hospitalization were observed and recorded in both groups. Results: After treatment, the total effective rate of the control group was 74.4%, the total effective rate of the treatment group was 90.7%, the difference was statistically significant (P <0.05); the improvement of the clinical symptoms in the treatment group was obviously better than that of the control group, The difference between the two groups was statistically significant (P <0.05). The total incidence of complications in the control group was 16.7% and the total complication rate in the treatment group was 4.6%. There was significant difference between the two groups (P <0.05). Conclusion: For patients with severe acute pancreatitis, conservative treatment with Xuebijing Injection combined with somatostatin on the basis of basic treatment has obvious clinical curative effect with few complications and can rapidly improve the clinical symptoms of patients.